Artículos por temáticas

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease

Deardorff WJ, Grossberg GT.

Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. doi: 10.2147/DDDT.S86463. eCollection 2016.

Hybrids: a new paradigm to treat Alzheimer's disease

Singh M, Kaur M, Chadha N, Silakari O.

Mol Divers. 2016 Feb;20(1):271-97. doi: 10.1007/s11030-015-9628-9. Epub 2015 Sep 2.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S.

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.

[Immunotherapy for Alzheimer's disease]

Falkentoft AC, Hasselbalch SG.

Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Xu MM, Ren WM, Tang XC, Hu YH, Zhang HY.

Acta Pharmacol Sin. 2016 Jun;37(6):719-30. doi: 10.1038/aps.2015.155. Epub 2016 Mar 21.

The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis

Zhuang S, Wang HF, Wang X, Li J, Xing CM.

J Clin Neurosci. 2016 Nov;33:32-38. doi: 10.1016/j.jocn.2016.02.036. Epub 2016 Jul 27.

Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy

Paterson RW, Abdi Z, Haines A, Schott JM.

Clin Neurol Neurosurg. 2016 May;144:64-6. doi: 10.1016/j.clineuro.2016.02.036. Epub 2016 Mar 3.

Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments

Liu CS, Ruthirakuhan M, Chau SA, Herrmann N, Carvalho AF, Lanctôt KL.

Curr Alzheimer Res. 2016;13(10):1134-44. doi: 10.2174/1567205013666160502122933.

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies

Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik C, Hof PR.

Biomolecules. 2016 Jan 6;6(1):6. doi: 10.3390/biom6010006.

Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors

Sallustio F, Studer V.

CNS Neurol Disord Drug Targets. 2016;15(6):647-59. doi: 10.2174/1871527315666160518123727.

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease

Maqbool M, Mobashir M, Hoda N.

Eur J Med Chem. 2016 Jan 1;107:63-81. doi: 10.1016/j.ejmech.2015.10.018. Epub 2015 Oct 21.

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review

Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD.

Oxid Med Cell Longev. 2016;2016:8590578. doi: 10.1155/2016/8590578. Epub 2016 Dec 27.

Association between Antipsychotic Drugs and Mortality in Older Persons with Alzheimer's Disease: A Systematic Review and Meta-Analysis

Zhai Y, Yin S, Zhang D.

J Alzheimers Dis. 2016 Mar 31;52(2):631-9. doi: 10.3233/JAD-151207.

Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer's Dementia. Focus on Non Neuronal Participants to Neurodegeneration)

Martorana A, Silvestrini M.

CNS Neurol Disord Drug Targets. 2016;15(6):646. doi: 10.2174/1871527315999160606154409.

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A.

Neural Plast. 2016;2016:8501693. doi: 10.1155/2016/8501693. Epub 2016 Jan 3.